NFC
MRNA icon

Northeast Financial Consultants’s Moderna MRNA Stock Holding History

Northeast Financial Consultants’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-2,210
Closed -$228K – 285
2023
Q3 		$228K Hold
2,210
– – 0.01% 252
2023
Q2 		$269K Hold
2,210
– – 0.02% 241
2023
Q1 		$339K Hold
2,210
– – 0.02% 235
2022
Q4 		$397K Hold
2,210
– – 0.03% 218
2022
Q3 		$261K Buy
+2,210
New +$335K 0.02% 282
2022
Q1 		– Sell
-1,000
Closed -$254K – 398
2021
Q4 		$254K Sell
1,000
-2,400
-71% -$702K 0.02% 307
2021
Q3 		$1.31M Buy
3,400
+2,400
+240% +$885K 0.09% 132
2021
Q2 		$235K Buy
+1,000
New +$179K 0.02% 323

Other funds holding MRNA

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.5B AUM 19.72% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Northeast Financial Consultants's MRNA Position: Q4 2023 in Review

Northeast Financial Consultants sold out of Moderna (MRNA) in Q4 2023, closing a stake of 2,210 shares — an estimated $228K sold.

Northeast Financial Consultants first reported a position in MRNA in Q2 2021 and held it in 8 quarters. The position peaked at $1.31M in Q3 2021. 884 funds tracked by Wall St. Rank hold MRNA as of Q4 2023.

  • Northeast Financial Consultants reported no remaining Moderna position as of Q4 2023 after selling out during the quarter.
  • Northeast Financial Consultants sold 2,210 Moderna shares in Q4 2023, an estimated $228K.
  • Northeast Financial Consultants first reported a position in Moderna in Q2 2021 and held it in 8 quarters.
  • Northeast Financial Consultants's Moderna position peaked at $1.31M in Q3 2021.
  • 884 funds tracked by Wall St. Rank held Moderna as of Q4 2023.

Based on Northeast Financial Consultants's 13F filing for Q4 2023, filed 14 Feb 2024.